Antifungal Agents

Correct Answer

B — Terbinafine

Rationale

Terbinafine is classified as an allylamine antifungal, a class defined by a synthetic allyl group attached to an amine core. Allylamines inhibit squalene epoxidase in the early ergosterol biosynthesis pathway. Flucytosine is a fluorinated pyrimidine antimetabolite that acts by disrupting fungal nucleic acid synthesis. Griseofulvin is a naturally occurring antifungal from Penicillium griseofulvum that inhibits fungal microtubule polymerization. Caspofungin is an echinocandin that inhibits beta-1,3-d-glucan synthase in the fungal cell wall.

Correct Answer

D — Flucytosine

Rationale

Flucytosine (5-fluorocytosine) is classified as a fluorinated pyrimidine antimetabolite. Its antifungal activity depends on conversion inside the fungal cell to 5-fluorouracil, which then disrupts both ribonucleic acid and deoxyribonucleic acid synthesis. This antimetabolite mechanism is entirely distinct from all other antifungal drug classes. Terbinafine is an allylamine that inhibits squalene epoxidase. Griseofulvin is a naturally occurring compound from Penicillium griseofulvum that inhibits fungal microtubule polymerization. Micafungin is an echinocandin cyclic lipopeptide that inhibits beta-1,3-d-glucan synthase.

Correct Answer

A — Griseofulvin

Rationale

Griseofulvin is a naturally occurring antifungal compound produced by the mold Penicillium griseofulvum. Its natural product origin is a distinctive classification property that sets it apart from the synthetic allylamine terbinafine and the synthetic fluorinated pyrimidine flucytosine. This source classification is part of griseofulvin's identity as one of the earliest antifungal agents used clinically. Flucytosine is a synthetic fluorinated pyrimidine compound. Terbinafine is a synthetic allylamine. Voriconazole is a synthetic second-generation triazole antifungal produced by chemical synthesis.

Correct Answer

C — Naftifine

Rationale

Naftifine is an allylamine antifungal classified as a topical-only agent. It lacks clinically significant systemic absorption and is used exclusively in topical preparations for superficial dermatophyte infections such as tinea pedis, tinea cruris, and tinea corporis. Terbinafine, the other primary allylamine in clinical use, is available both as an oral systemic formulation and as topical cream; the oral form is used for onychomycosis and tinea capitis where topical penetration to the site of infection is insufficient. Griseofulvin is a separate antifungal class from allylamines and is available as an oral formulation. Flucytosine is a fluorinated pyrimidine antimetabolite available for oral and historically intravenous administration.

Correct Answer

C — Flucytosine

Rationale

Flucytosine is classified as the antifungal used in combination with amphotericin B for induction therapy of cryptococcal meningitis. This combination-use classification is a defining categorical feature of flucytosine in antifungal pharmacology: it is not used as monotherapy because resistance emerges rapidly, and its primary clinical role is as a partner drug in the amphotericin B plus flucytosine induction regimen for cryptococcal meningitis, where the combination achieves fungicidal killing of Cryptococcus neoformans superior to either agent alone. Terbinafine is an allylamine antifungal classified for dermatophyte infections — onychomycosis and tinea — and has no role in cryptococcal or any systemic yeast or mold infection. Griseofulvin is classified for dermatophyte infections of skin, hair, and nails only, with no indication for systemic fungal infections. Naftifine is a topical-only allylamine with no systemic indication of any kind.

Correct Answer

D — Griseofulvin

Rationale

Griseofulvin is classified as an antifungal agent with an approved indication limited exclusively to dermatophyte infections — specifically infections of the skin (tinea corporis, tinea cruris, tinea pedis), hair (tinea capitis), and nails (onychomycosis) caused by susceptible Trichophyton, Microsporum, and Epidermophyton species. Its antifungal activity is dermatophyte-specific: it has no approved or clinically established role against Candida, Aspergillus, Cryptococcus, or any other non-dermatophyte pathogen. This narrow approved indication is a categorical feature of griseofulvin that distinguishes it from terbinafine, which also covers dermatophytes but lacks a broader invasive infection role, and is fundamentally different from agents with broader approved indications. Flucytosine is approved exclusively for systemic Candida and Cryptococcus infections — the opposite spectrum. Amphotericin B has the broadest approved indication spectrum among antifungal agents, covering most pathogenic fungal organisms.

Correct Answer

C — Inhibition produces two simultaneous consequences — ergosterol depletion and massive intracellular accumulation of squalene, which is directly toxic to the fungal cell membrane at high concentrations

Rationale

Terbinafine inhibits squalene epoxidase, the enzyme that converts squalene to squalene epoxide — the step immediately preceding lanosterol formation in the sterol biosynthesis pathway. This inhibition produces two consequences simultaneously: ergosterol depletion, which disrupts fungal membrane fluidity and function, and massive intracellular accumulation of squalene, which is directly toxic to the fungal cell membrane at the high concentrations that build up. The combination of ergosterol depletion and squalene toxicity produces fungicidal activity against dermatophytes, in contrast to the fungistatic effect of azoles against the same organisms. Azoles act downstream at lanosterol 14-alpha-demethylase and produce only ergosterol depletion with toxic sterol accumulation — the squalene toxicity is specific to squalene epoxidase inhibition. Terbinafine does not bind tubulin.

Correct Answer

A — Terbinafine is incorporated into the nail plate during growth and persists in nail tissue for months after plasma concentrations fall, continuing to act on dermatophytes as the nail grows out

Rationale

Terbinafine is highly lipophilic and extensively distributed into skin, nails, hair, and adipose tissue, achieving concentrations in keratinized tissues that substantially exceed plasma concentrations. It is incorporated into the nail plate during nail growth and remains in the nail even after the oral course ends and plasma concentrations fall. This pharmacokinetic property means the drug continues to work against dermatophytes infecting the nail long after the patient stops taking tablets, which is the basis for the relatively short treatment courses used in onychomycosis compared to older antifungals. The terminal half-life of terbinafine reflects slow release from tissue compartments, not a 30-day plasma half-life. Terbinafine does not work through immune induction and does not have a pharmacologically active nail matrix metabolite that extends activity.

Correct Answer

D — Terbinafine is superior for Trichophyton tonsurans, the dominant cause of tinea capitis in the United States; griseofulvin retains a first-line role for Microsporum canis tinea capitis, where terbinafine performs poorly

Rationale

Terbinafine and griseofulvin have complementary species-specific activity profiles for tinea capitis. Terbinafine is superior for Trichophyton tonsurans — the organism responsible for the majority of tinea capitis in the United States and sub-Saharan Africa — achieving higher cure rates than griseofulvin against this species. Griseofulvin retains a clear first-line role for tinea capitis caused by Microsporum canis, where terbinafine performs poorly. Microsporum canis is more common in Europe and certain other regions. The clinical implication is that treatment selection should consider the likely causative species based on geographic epidemiology and culture results when available. Both drugs remain recommended in current guidelines for their respective species niches rather than either replacing the other entirely.

Correct Answer

B — Entry via cytosine permease; conversion by fungal cytosine deaminase to 5-fluorouracil, which is then processed to fraudulent nucleotides that inhibit thymidylate synthase and disrupt ribonucleic acid synthesis

Rationale

Flucytosine enters fungal cells through a cytosine permease transporter expressed in susceptible fungi but absent from mammalian cells — the basis for selective antifungal toxicity. Once inside, fungal cytosine deaminase converts flucytosine to 5-fluorouracil (5-FU). The 5-FU is then converted through the thymidylate synthase pathway to fraudulent nucleotides that are incorporated into fungal ribonucleic acid and deoxyribonucleic acid. The 5-FU metabolites inhibit thymidylate synthase, blocking thymidine monophosphate synthesis required for deoxyribonucleic acid replication, and are incorporated into ribonucleic acid as fraudulent bases that disrupt protein synthesis. This dual disruption of both deoxyribonucleic acid and ribonucleic acid metabolism gives flucytosine fungicidal activity against susceptible organisms. Mammalian cells lack significant cytosine deaminase activity, providing selectivity — although gut bacteria can deaminate flucytosine to 5-FU, explaining some of the systemic toxicity that occurs.

Correct Answer

C — Resistance emerges rapidly — typically within days to weeks — through mutations that reduce cytosine deaminase expression or cytosine permease activity, eliminating the drug's mechanism of action

Rationale

Flucytosine monotherapy is avoided because resistance emerges rapidly — typically within days to weeks — through mutations in the fungal cell that reduce cytosine deaminase expression or cytosine permease activity. When cytosine deaminase is reduced or absent, flucytosine cannot be converted to 5-fluorouracil and loses all antifungal activity. When cytosine permease is mutated, flucytosine cannot enter the fungal cell. Either mutation eliminates the drug's mechanism of action completely. Combining flucytosine with amphotericin B prevents resistance emergence because amphotericin B acts through an entirely different mechanism and because it increases membrane permeability, enhancing flucytosine uptake even in organisms with reduced cytosine permease activity. While flucytosine toxicity from gut bacterial conversion of the drug to 5-fluorouracil is a real concern, it is not the reason monotherapy fails — resistance emergence is the primary problem.

Correct Answer

A — Flucytosine toxicity is concentration-dependent; the peak concentration of 130 mg/L exceeds the upper target of 100 mg/L; and because flucytosine is renally eliminated, amphotericin B-induced nephrotoxicity caused drug accumulation to toxic levels

Rationale

Flucytosine bone marrow suppression — manifesting as leukopenia, thrombocytopenia, and less commonly anemia — is concentration-dependent and correlates with peak concentrations above 100 mg/L. The target peak concentration range is 50 to 100 mg/L, and the upper limit of 100 mg/L defines the toxicity threshold. Flucytosine is excreted almost entirely unchanged by the kidneys through glomerular filtration. When amphotericin B causes nephrotoxicity and reduces creatinine clearance — as it commonly does during combination therapy — flucytosine clearance falls and concentrations rise, potentially crossing the toxicity threshold even at doses that were safe initially. This is why renal function and flucytosine concentrations must be monitored closely during combination therapy, and why dose adjustment based on creatinine clearance is mandatory. The toxicity is not a direct pharmacodynamic synergy between the two drugs, is not an idiosyncratic reaction at this concentration, and does not involve mammalian cytosine deaminase conversion in bone marrow.

Correct Answer

D — Binding to tubulin and inhibiting microtubule polymerization, disrupting the mitotic spindle required for cell division; fungistatic, with activity limited exclusively to dermatophytes

Rationale

Griseofulvin binds to tubulin and inhibits microtubule polymerization in fungal cells, disrupting mitotic spindle formation required for cell division. It also binds to keratin precursor proteins in host cells, which concentrates it in actively growing keratin — skin, hair, and nails. The antifungal effect is fungistatic: griseofulvin arrests fungal growth but does not kill existing organisms, so new keratin formed during treatment contains drug while infected keratin grows out and is shed. This growth-displacement mechanism requires prolonged treatment courses. Griseofulvin is active only against dermatophytes — Trichophyton, Microsporum, and Epidermophyton species — and has no activity against Candida, Aspergillus, or any non-dermatophyte organism. This tubulin-binding mechanism is entirely distinct from ergosterol targeting (polyenes, azoles, allylamines), cell wall targeting (echinocandins), and nucleic acid disruption (flucytosine).

Correct Answer

B — Disulfiram-like reaction with alcohol; teratogenicity in animal models contraindicating use in pregnancy; reduced oral contraceptive efficacy through cytochrome P450 3A4 induction

Rationale

Griseofulvin has three distinctive properties captured in option B. First, it produces a disulfiram-like reaction with alcohol — flushing, tachycardia, and nausea — requiring patients to avoid alcohol during therapy. Second, griseofulvin is teratogenic in animal models, making it contraindicated during pregnancy; female patients of reproductive age must be counseled about this risk. Third, griseofulvin induces hepatic cytochrome P450 3A4 and reduces plasma concentrations of co-administered cytochrome P450 3A4 substrates, including the ethinyl estradiol component of combined oral contraceptives, reducing their contraceptive efficacy; patients must be counseled to use additional contraceptive methods during treatment and for a period afterward. Griseofulvin does not prolong the QT interval, does not cause nephrotoxicity, does not inhibit cytochrome P450 2C9, and does not cause bone marrow suppression. Drug-induced lupus is a rare adverse effect that occurs in a small fraction of patients, not more than 10 percent.

Correct Answer

C — Griseofulvin, because terbinafine performs poorly against Microsporum canis and griseofulvin retains a first-line role specifically for this species

Rationale

Griseofulvin is the preferred agent for tinea capitis caused by Microsporum canis. While terbinafine is superior to griseofulvin for tinea capitis caused by Trichophyton tonsurans — the dominant species in the United States — terbinafine performs poorly against Microsporum canis. Griseofulvin's ability to concentrate in keratinized tissues including the scalp and hair follicle, combined with its specific activity against Microsporum, makes it the agent of choice when Microsporum canis is identified or strongly suspected. Terbinafine achieves higher cure rates than griseofulvin overall in comparative trials, but this advantage is driven by its superiority against Trichophyton tonsurans, not Microsporum. Fluconazole is not a first-line agent for tinea capitis. Itraconazole is an alternative option but is not superior to griseofulvin for Microsporum canis infections.

Correct Answer

A — Amphotericin B increases fungal cell membrane permeability, which enhances flucytosine uptake via cytosine permease, allowing lower concentrations of both drugs to achieve fungicidal killing superior to either agent alone

Rationale

The combination of amphotericin B plus flucytosine is synergistic because amphotericin B increases fungal cell membrane permeability by forming pores, which enhances the uptake of flucytosine via the cytosine permease transport system. This allows lower concentrations of both drugs to achieve fungicidal killing than either could achieve alone. The combination produces more rapid clearance of Cryptococcus from the cerebrospinal fluid — the key determinant of early mortality in cryptococcal meningitis — compared to amphotericin B monotherapy. Clinical trial evidence, including the ACTA trial, demonstrated that one week of amphotericin B plus flucytosine reduced ten-week mortality compared to two weeks of amphotericin B monotherapy. Flucytosine acts on nucleic acid synthesis, not ergosterol synthesis, so there is no complementary ergosterol pathway inhibition. Flucytosine does not chelate amphotericin B. Both agents have reasonable cerebrospinal fluid penetration, and that is not the basis for the synergy.

Correct Answer

B — Terbinafine inhibits cytochrome P450 2D6, the primary enzyme responsible for nortriptyline metabolism, causing drug accumulation and enhanced anticholinergic and cardiac toxicity

Rationale

Terbinafine is a potent inhibitor of cytochrome P450 2D6, the isoform responsible for metabolizing nortriptyline and other tricyclic antidepressants. By inhibiting cytochrome P450 2D6, terbinafine reduces nortriptyline clearance and allows the drug to accumulate to concentrations well above the therapeutic range, producing signs of tricyclic antidepressant toxicity: dry mouth, urinary hesitancy, and constipation from anticholinergic effects; tachycardia from both anticholinergic and direct cardiac effects; and risk of cardiac arrhythmia at higher concentrations. This interaction is clinically important because oral terbinafine courses for onychomycosis last 12 weeks — long enough for the drug-drug interaction to reach full effect. Patients on cytochrome P450 2D6-metabolized medications including tricyclic antidepressants, certain beta-blockers (metoprolol), and certain antiarrhythmics should have those drugs monitored or dose-adjusted when terbinafine is initiated. Terbinafine does not induce cytochrome P450 3A4, does not compete for renal tubular secretion, and does not inhibit P-glycoprotein to a clinically relevant degree.

Correct Answer

B — Griseofulvin induces cytochrome P450 3A4, increasing the hepatic metabolism of ethinyl estradiol and reducing its plasma concentrations below the level required for ovulation suppression

Rationale

Griseofulvin induces hepatic cytochrome P450 3A4, which metabolizes ethinyl estradiol, the estrogen component of combined oral contraceptives. The increased metabolism reduces ethinyl estradiol plasma concentrations, potentially reducing them below the threshold required for reliable ovulation suppression and consequent contraceptive efficacy. This interaction is clinically established and requires that patients taking griseofulvin be counseled to use an additional non-hormonal contraceptive method during therapy and for at least one month after completing the course. Griseofulvin does not inhibit progesterone receptor binding, does not inhibit intestinal P-glycoprotein, and does not increase gastrointestinal motility. The mechanism is cytochrome P450 3A4 induction leading to increased hepatic first-pass and systemic metabolism of the estrogen component.